Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2008

01-02-2008

A randomized, double-blind trial of the interaction between cranberry juice and warfarin

Authors: Jack Ansell, Maryellen McDonough, Jerold S. Harmatz, David J. Greenblatt

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2008

Login to get access

Excerpt

Background Therapeutic warfarin therapy is highly influenced by concomitant drug therapy or dietary factors by effecting warfarin metabolism or vitamin K status. Cranberry juice (CJ) was recently implicated to influence the INR in patients on warfarin based on a number of brief anecdotal or case reports. This study was designed to determine what influence, if any, daily cranberry juice consumption has on INR levels and plasma warfarin concentrations in patients stably anticoagulated with warfarin. Methods Patients on warfarin for a variety of indications from a population of anticoagulation clinic patients were selected because of their past history of stable anticoagulation and willingness to participate in the study. Major inclusions criteria required a therapeutic INR range of 2.0–3.0, no hepatic or renal dysfunction, a stable INR (1.7–3.3) on at least two measurements within 8 weeks prior to study entry, and informed consent. The study consisted of a 2 week lead-in phase (with weekly INRs in range); a 2 week intervention phase (double-blind daily consumption of an 8 oz. glass of cranberry juice or placebo); and a one week follow-up (35 day total). Any patient with an out of range INR during the intervention phase ceased the intervention but continued through follow-up. Results Thirty patients were randomized, 14 to CJ and 16 to placebo. 28.6% (4/14) in the CJ group developed a minimally elevated INR and 7.1% (1/14) developed a low INR during the intervention phase. 25% (4/16) in the control group developed a minimally elevated INR during the intervention. There was so significant difference in the mean INRs from each group on each day of measurement except for day 11 of the intervention phase when the CJ group was significantly higher than the placebo group (P < 0.02), although on day 15 (end of intervention) the mean INRs from both groups were identical. There was no difference between R- or S-warfarin plasma levels at corresponding times, nor was there a significant change over time in either enantiomer. Last, there was no significant difference in peak warfarin levels during the lead-in phase or during the treatment phase. There was actually a slight drop in both groups during the treatment phase. Conclusion A daily 8 oz. glass of cranberry juice appears to have no significant effect on the INR in patients on warfarin therapy compared to placebo. …
Metadata
Title
A randomized, double-blind trial of the interaction between cranberry juice and warfarin
Authors
Jack Ansell
Maryellen McDonough
Jerold S. Harmatz
David J. Greenblatt
Publication date
01-02-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0120-y

Other articles of this Issue 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.